Evidence map›Paper›PMID 29228201›Full record

Trial reportBrain : a journal of neurology2018

Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.

Val J Lowe, Heather J Wiste, Matthew L Senjem, Stephen D Weigand, Terry M Therneau, Bradley F Boeve, Keith A Josephs, Ping Fang, Mukesh K Pandey, Melissa E Murray and 11 more

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Brain : a journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 203 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
203citing papers in PubMed, 1 pooled it
17.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

203 citing papers in PubMed, 1 synthesis or guideline pooled it, 307 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Visual versus quantitative tau-PET Braak staging in Alzheimer's disease using [European journal of nuclear medicine and molecular imaging · 2026
    Article
  7. Glial Cells in Behavioral and Psychological Symptoms of Alzheimer's Disease.International journal of molecular sciences · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Tau PET overlap index correlation with neuropathological findings.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  12. Article
  13. Article
  14. Elevated NaInternational journal of molecular sciences · 2026
    Article
  15. Fyn-Saracatinib Complex Structure Reveals an Active State-like Conformation.International journal of molecular sciences · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Characterizing amyloid and tau positron emission tomography-based stages across the clinical continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article

143 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Heather J WisteDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Matthew L SenjemDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Stephen D WeigandDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Terry M TherneauDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Ping FangDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Mukesh K PandeyDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Kejal KantarciDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
David T JonesDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Christopher G SchwarzDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Michelle M MielkeDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Rosebud O RobertsDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · USMayo Clinic in Florida · USMayo Clinic · US

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Longitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2M
Prevention of Alzheimer's disease in women: risks and benefits of hormone therapyRF1AG057547 · NIA · MAYO CLINIC ROCHESTER · PI GLEASON, CAREY E, KANTARCI, KEJAL · 2017 to 2020
$11.1M
Longitudinal Multi-modal Imaging in Progressive Supranuclear Palsy SyndromesR01NS089757 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2015 to 2024
$5.6M
Development, Validation, and Application of an Imaging based CVD ScaleR01NS097495 · NINDS · MAYO CLINIC ROCHESTER · PI VEMURI, PRASHANTHI · 2016 to 2020
$2.9M
The role of acetylation in regulating pathophysiology of tauR01NS089544 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD, WOLOZIN, BENJAMIN L · 2014 to 2018
$1.9M
PIB PET Scanning in Speech and Language Based DementiasR01DC010367 · NIDCD · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A · 2010 to 2014
$1.7M
Manipulating tau's posttranslational modifications to block disease progression in vivoR21NS094489 · NINDS · MAYO CLINIC JACKSONVILLE · PI COOK, CASEY N · 2015 to 2016
$430k
NIA NIH HHS P50 AG016574NIA NIH HHS RF1 AG057547NIA NIH HHS U01 AG006786NIDCD NIH HHS R01 DC010367NINDS NIH HHS R01 NS089544NINDS NIH HHS R01 NS089757NINDS NIH HHS R01 NS097495NINDS NIH HHS R21 NS094489NINDS NIH HHS U01 NS100620
6 · The paper itself

Abstract

See Herholz (doi:10.1093/brain/awx340) for a scientific commentary on this article.Autopsy data have proposed that a topographical pattern of tauopathy occurs in the brain with the development of dementia due to Alzheimer's disease. We evaluated the findings of tau-PET to better understand neurofibrillary tangle development as it is seen in cognitively unimpaired and impaired individuals. The evolution of Alzheimer's disease tauopathy in cognitively unimpaired individuals needs to be examined to better understand disease pathogenesis. Tau-PET was performed in 86 cognitively impaired individuals who all had abnormal amyloid levels and 601 cognitively unimpaired individuals. Tau-PET findings were assessed for relationships with clinical diagnosis, age, and regional uptake patterns relative to Braak stage. Regional and voxel-wise analyses were performed. Topographical findings from tau-PET were characterized using hierarchical clustering and clinical characteristic-based subcategorization. In older cognitively unimpaired individuals (≥50 years), widespread, age-related elevated tau signal was seen among those with normal or abnormal amyloid status as compared to younger cognitively unimpaired individuals (30-49 years). More frequent regional tau signal elevation throughout the brain was seen in cognitively unimpaired individuals with abnormal versus normal amyloid. Elevated tau signal was seen in regions that are considered high Braak Stage in cognitively unimpaired and cognitively impaired individuals. Hierarchical clustering and clinical characteristic-based categorizations both showed different patterns of tau signal between groups such as greater tau signal in frontal regions in younger onset Alzheimer's disease dementia participants (most of whom had a dysexecutive clinical presentation). Tau-PET signal increases modestly with age throughout the brain in cognitively unimpaired individuals and elevated tau is seen more often when amyloid brain accumulation is present. Tau signal patterns in cognitively unimpaired correspond to early Braak stage but also suggest tangle involvement in extra-medial temporal and extra-temporal regions that are considered more advanced in the Braak scheme even when amyloid negative. Our findings also suggest the possibility of widespread development of early tangle pathology rather than a pattern defined exclusively by adjacent, region-to-region spread, prior to onset of clinical symptoms. Distinct patterns of neurofibrillary tangle deposition in younger-onset Alzheimer's disease dementia versus older-onset Alzheimer's disease dementia provide evidence for variability in regional tangle deposition patterns and demonstrate that different disease phenotypes have different patterns of tauopathy. Pathological correlation with imaging is needed to assess the implications of these observations.

Indexed as

Brain MappingAdultAgedAged, 80 and overAgingAlzheimer DiseaseBrainCluster AnalysisCognition DisordersFemaleHumansImaging, Three-DimensionalMaleMiddle AgedNeurofibrillary TanglesPositron-Emission Tomographytau ProteinsAlzheimer’s diseaseamyloid-PETdementiamild cognitive impairmenttau-PET

Identifiers

PMID29228201
PMCPMC5837250
OpenAlexW2774369241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.